TONMYA Beats Placebo on FIQR in Both Phase 3 Fibromyalgia Trials

Image
TONMYA Beats Placebo on FIQR in Both Phase 3 Fibromyalgia Trials

BERKELEY HEIGHTS, N.J. -- November 19, 2026 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) reported that TONMYA fibromyalgia treatment beat placebo on both the symptoms and function domains of the Fibromyalgia Impact Questionnaire-Revised (FIQR) at Week 14 in two Phase 3 trials. The result was significant at p≤0.001 in RESILIENT and nominally significant at p0.01 in RELIEF.

Tonix presented the analysis at the IASP 2026 World Congress on Pain in Bangkok, held October 26-30, 2026. That is about 11 months after the November 2025 commercial launch of the drug, which the FDA approved on August 15, 2025.

RESILIENT meets the FIQR bar at p≤0.001 while RELIEF reaches only nominal significance

The FIQR domains were key secondary endpoints in both trials. The primary endpoint was the change in weekly average daily pain score on a 0-10 numeric rating scale at Week 14. Tonix says TONMYA delivered statistically and clinically significant improvement over placebo on that endpoint in both studies.

TONMYA showed a greater reduction from baseline than placebo in both FIQR domains at Weeks 2, 6, 10 and 14 in both studies. Tonix attributes the "nominal" label on RELIEF's Week 14 result to the hierarchical testing of endpoints used to control type 1 error. As a result, the release describes only RESILIENT's Week 14 FIQR results as statistically significant.

Tonix did not disclose enrolment figures or the size of the FIQR score differences versus placebo.

The company says TONMYA was generally well tolerated, with no new safety signals. The most common treatment-emergent adverse events were local oral administration site reactions.

Trial design gives TONMYA 12 weeks at the 5.6 mg dose

Both trials were randomized, double-blind and placebo-controlled, with 1:1 allocation. Participants met the 2016 American College of Rheumatology diagnostic criteria for fibromyalgia. The TONMYA arm took 2.8 mg at bedtime for two weeks, then 5.6 mg at bedtime through Week 14. By our calculation, that is 12 of the 14 weeks at a dose double the starting level.

FIQR assessments were taken at four-week intervals from Week 2 to Week 14, with Week 14 as the pre-specified timepoint of interest. The FIQR measures fibromyalgia burden over the prior seven days.

CEO Seth Lederman said the data reinforce TONMYA's role as a "first-line, non-opioid treatment option". That is the company's own characterization of the drug's role.

TONMYA's first commercial year ends with U.S. exclusivity expected to run to 2034

Tonix describes TONMYA as the first new prescription fibromyalgia medicine approved in more than 15 years. The company says more than 10 million U.S. adults have fibromyalgia, predominantly women.

Five U.S. patents, issued between May 2017 and August 2020, cover the formulation. Tonix expects them to give TONMYA U.S. market exclusivity until 2034. That is roughly eight years after the congress and about nine years after FDA approval, by our calculation.

Tonix also sells the acute migraine products Zembrace SymTouch and Tosymra. It is running Phase 2 studies of the same active formulation, TNX-102 SL, in major depressive disorder and acute stress disorder/acute stress reaction.

Published by:
fairsonline_team
Products
Target market(s)
News Type